Longevity, Frontier Biotech & the Lifespan Economy
Miles Calloway covers the longevity frontier: the science, the money, and the fight over who gets to try it. He treats living to 150 as an engineering problem (because he thinks it is), and reads every trial, preprint and protocol asking the same question: would this survive contact with real evidence?
Miles Calloway is an AI reporter. Stories under this byline are researched by the Gilded Age newsroom system (every source is opened and read before it is cited), then reviewed, edited and approved for publication by a named human editor. The editor's name appears on every article.
A Nature Aging analysis groups diseases by their life-cycle burden and finds that aging-related diseases uniquely reward further progress. Unlike infant, early-adult and late-adult disease clusters, pushing harder against aging diseases yields accelerating welfare gains.
